Elacestrant dihydrochloride
CAS No. 1349723-93-8
Elacestrant dihydrochloride ( RAD-1901 dihydrochloride )
产品货号. M11413 CAS No. 1349723-93-8
Elacestrant (RAD-1901) 是一种新型口服生物可利用的小分子选择性雌激素受体降解剂 (SERD)。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥2017 | 有现货 |
|
| 10MG | ¥3208 | 有现货 |
|
| 25MG | ¥5387 | 有现货 |
|
| 50MG | ¥7671 | 有现货 |
|
| 100MG | ¥10368 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Elacestrant dihydrochloride
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Elacestrant (RAD-1901) 是一种新型口服生物可利用的小分子选择性雌激素受体降解剂 (SERD)。
-
产品描述Elacestrant (RAD-1901) is a novel, orally bioavailable small-molecule selective estrogen receptor degrader (SERD); inhibits ERα expression in MCF-7 cells (IC50=0.6 nM); induces the degradation of ER, inhibits ER-mediated signaling and growth of ER+ breast cancer cell lines in vitro and in vivo, and significantly inhibits tumor growth of multiple PDX models.Breast Cancer Phase 2 Clinical.
-
体外实验Cell Proliferation Assay Cell Line:ER-positive MCF-7 cells (Estradiol (E2)-stimulated)Concentration:0-1 μM Incubation Time:48 h Result:Showed antiproliferative activity on cells.Western Blot Analysis Cell Line:MCF-7 cells Concentration:0.5 nM-10 μM Incubation Time:48 h Result:Inhibited ERα expression (EC50 of 0.6 nM) in a dose-dependent manner.Western Blot AnalysisCell Line:MCF7, T47D, and HCC1428 cells Concentration:0-1 μM Incubation Time:24 or 48 h Result:Decreased the expression of estrogen receptor protein.
-
体内实验——
-
同义词RAD-1901 dihydrochloride
-
通路Endocrinology/Hormones
-
靶点Estrogen Receptor/ERR
-
受体Estrogen Receptor/ERR
-
研究领域Cancer
-
适应症Breast Cancer
化学信息
-
CAS Number1349723-93-8
-
分子量531.5568
-
分子式C30H40Cl2N2O2
-
纯度>98% (HPLC)
-
溶解度DMSO: 17.6 mg/mL
-
SMILES——
-
化学全称2-Naphthalenol, 6-[2-[ethyl[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydro-, hydrochloride (1:2), (6R)-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Wardell SE, et al. Endocr Relat Cancer. 2015 Oct;22(5):713-24.
2. Garner F, et al. Anticancer Drugs. 2015 Oct;26(9):948-56.
3. Bihani T, et al. Clin Cancer Res. 2017 May 4. pii: clincanres.2561.2016.
021-51111890
购物车()
sales@molnova.cn

